HMD Develops Dispojekt To Help Reduce Needle Stick Injuries

New Delhi: Hindustan Syringes and Medical Devices (HMD) has launched first-of-its kind Dispojekt single use syringes with safety needle, which further strengthens India’s position in becoming global powerhouse in medical devices.

With the revolutionary Dispojekt safety syringes, HMD aims to reduce prevalence of accidental Needle Stick Injuries (NSIs) among health workers, reduction of infection control cost and that of disposal and training, offering a long term positive financial impact on the healthcare sector. Domestic manufactured, technologically advanced products will provide India a global edge in the realm of R&D and leapfrog indigenous players to meet the highly demanding global market for sharp injury prevention syringes.

The use of safety needles in healthcare settings offer numerous cost benefits. They reduce healthcare worker injuries, lowering costs from potential disease treatment and potential long-term health issues. By minimising needle stick injuries, they also decrease expenses for post-exposure prophylaxis and associated healthcare costs. Moreover, safety needles mitigate compensation claims, absenteeism, and can lead to lower health insurance premiums, while also reducing product and packaging footprints for cost and environmental savings. They assist in creating a safer and more reliable workplace environment for healthcare workers.

According to research, the prevalence of NSIs among healthcare workers in India is between 57% and 73%. In fact, approximately 54% of NSIs are reported because of using hypodermic needles. Many instances of NSIs go unreported, making it a way more serious problem than it appears.

Related Posts

Cancer cure must not be hostage to Big Pharma

In recent years, immunotherapy has expanded the limits of cancer treatment. Therapies that harness the body’s immune system to fight malignant cells have improved survival rates in cancers once considered…

GLP-1 drugs emerge as a new option for Indian women bat­tling PCOS

Pune:- A woman, 34, dia­gnosed with poly­cystic ovary syn­drome, or PCOS, as a teen­ager, saw her first nat­ural men­strual cycle in Feb­ru­ary—six months after start­ing Moun­jaro for weight man­age­ment. This…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Cancer cure must not be hostage to Big Pharma

Cancer cure must not be hostage to Big Pharma

GLP-1 drugs emerge as a new option for Indian women bat­tling PCOS

GLP-1 drugs emerge as a new option for Indian women bat­tling PCOS

Aurobindo Pharma gains after receving USFDA nod for Glycerol Phenylbutyrate Oral Liquid

Aurobindo Pharma gains after receving USFDA nod for Glycerol Phenylbutyrate Oral Liquid

Legal Loopholes Stall Crackdown On Interstate Fake Drug Rackets In India

Legal Loopholes Stall Crackdown On Interstate Fake Drug Rackets In India

Patna HC Rules Phenothiazine & Promethazine Not Narcotic Or Psychotropic Substances Under NDPS Act

Patna HC Rules Phenothiazine & Promethazine Not Narcotic Or Psychotropic Substances Under NDPS Act

COMT Inhibitors May Fuel Gut Bacteria That Degrade Levodopa In Parkinson’s Patients

COMT Inhibitors May Fuel Gut Bacteria That Degrade Levodopa In Parkinson’s Patients